Anika Therapeutics annual debt-to-ebitda ratio
2010
2011
2012
2019
2021
2022
2023
2024
Anika Therapeutics Debt-to-EBITDA Ratio Growth & History (ANIK)
Anika Therapeutics's debt-to-ebitda ratio was 14.54 for fiscal 2024.
View full Anika Therapeutics company overviewAnika Therapeutics annual debt-to-ebitda ratio history
| Fiscal year | Period ended | Debt-to-EBITDA ratio | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | 14.54 | 10.73 | +281.56% |
| 2023 | 2023-12-31 | 3.81 | 1.03 | +37.22% |
| 2022 | 2022-12-31 | 2.78 | 0.66 | +31.31% |
| 2021 | 2021-12-31 | 2.12 | — | — |
| 2019 | 2019-12-31 | 0.57 | — | — |
| 2012 | 2012-12-31 | 0.40 | −0.23 | −36.46% |
| 2011 | 2011-12-31 | 0.62 | −0.56 | −47.13% |
| 2010 | 2010-12-31 | 1.18 | — | — |
Anika Therapeutics quarterly debt-to-ebitda ratio
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q4.21
Q1.22
Q4.22
Q1.23
Q2.23
Q4.23
Q1.24
Q2.24
Q4.24
Q3.25
Q2.26
| Fiscal quarter | Period ended | Debt-to-EBITDA ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 50.50 | — | — |
| Q3 2025 | 2025-09-30 | 1.16 | — | — |
| Q4 2024 | 2024-12-31 | 14.54 | 10.73 | +281.56% |
| Q2 2024 | 2024-06-30 | 1.45 | −29.41 | −95.31% |
| Q1 2024 | 2024-03-31 | 1.63 | −19.97 | −92.45% |
| Q4 2023 | 2023-12-31 | 3.81 | 1.03 | +37.22% |
| Q2 2023 | 2023-06-30 | 30.86 | — | — |
| Q1 2023 | 2023-03-31 | 21.60 | 17.34 | +406.13% |
| Q4 2022 | 2022-12-31 | 2.78 | 0.66 | +31.31% |
| Q1 2022 | 2022-03-31 | 4.27 | — | — |
| Q4 2021 | 2021-12-31 | 2.12 | — | — |
| Q2 2020 | 2020-06-30 | 3.21 | 2.66 | +480.03% |
| Q1 2020 | 2020-03-31 | 0.57 | −0.00 | −0.22% |
| Q4 2019 | 2019-12-31 | 0.57 | — | — |
| Q3 2019 | 2019-09-30 | 0.50 | — | — |
| Q2 2019 | 2019-06-30 | 0.55 | — | — |
| Q1 2019 | 2019-03-31 | 0.57 | — | — |
| Q3 2013 | 2013-09-30 | 0.24 | −0.23 | −48.54% |
| Q2 2013 | 2013-06-30 | 0.30 | −0.15 | −33.63% |
| Q1 2013 | 2013-03-31 | 0.35 | −0.18 | −33.73% |
| Q4 2012 | 2012-12-31 | 0.40 | −0.23 | −36.46% |
| Q3 2012 | 2012-09-30 | 0.47 | — | — |
| Q2 2012 | 2012-06-30 | 0.45 | — | — |
| Q1 2012 | 2012-03-31 | 0.53 | — | — |
| Q4 2011 | 2011-12-31 | 0.62 | — | — |
Anika Therapeutics debt-to-ebitda ratio trends
Over the last five fiscal years, Anika Therapeutics's debt-to-ebitda ratio increased from 0.57 to 14.54, a change of 13.97. The latest reported quarter, Q2 2026, shows 50.50.
About the metric
What the debt-to-EBITDA ratio means
Debt-to-EBITDA compares interest-bearing debt with operating earnings before interest, taxes, depreciation, and amortization. It is commonly used to assess leverage, but it is generally unsuitable for banks and other financial companies.
Calculation and source
How debt-to-EBITDA is calculated
TickerStat divides period-end total debt by annual EBITDA. Quarterly observations use trailing-12-month EBITDA. Periods with zero or negative EBITDA are excluded because the leverage multiple would not be meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Anika Therapeutics source filings ↗